Oppenheimer Comments On Intercept As FLINT Manuscript Has Been Accepted For Publication In A Journal

Oppenheimer analyst Akiva Felt maintained an Outperform rating on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), as a webpage from Johns Hopkins School of Public Health states that the FLINT manuscript has been accepted for publication by The Lancet medical journal. No price target was provided.

Felt commented: “Although ICPT has already disclosed key datapoints from FLINT, investors have been eager to see the full data in publication to answer lingering questions related to efficacy and safety. As we discussed previously, management was not able to give specific clarity on the timing of a FLINT publication as the submissions are being handled by the NASH CRN group and the peer review process is inherently unpredictable. If the manuscript has indeed been accepted by The Lancet, we could see a publication in the short term, as the journal’s fast-track process aims to get articles published within four weeks of submission.”

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Akiva Felt has a total average return of 56.3% and a 76.0% success rate. Felt has a 174.4% average return when recommending ICPT, and is ranked #27 out of 3358 analysts.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts